Clin2
NCT06499025Possibly a fitEnrolling by invitation

T-cell therapy for a type of AML with the AML1-ETO gene

AMLt(8;21)Neoantigen

Treatments studied

CyclophosphamideDecitabine

Part of Blood & lymphatic, Cancer clinical trials.

This trial tests a personalized cell therapy that uses your own immune cells (T cells) to target a specific protein (AML1-ETO) found in certain AML cells. It is for patients whose leukemia has come back or not gone away after standard treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
16 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old
  • You have a type of AML called t(8;21) or persistent AML1-ETO gene after chemotherapy
  • Your HLA type is either A*11:01 or A*02:01 (a blood test will check this)
  • Your leukemia has not responded to or has returned after at least 2 cycles of treatment
  • You have a good performance status (ECOG score of 0 or 1, meaning you can do daily activities)
  • You are willing to have blood drawn to collect cells for the therapy

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07342244Not yet recruiting
CLL1 car-t with stem cell transplant for aml

This trial tests a two-step treatment: first a targeted immune cell therapy (CLL1 CAR-T) to attack leukemia cells, followed by a stem cell transplant to rebuild healthy blood cells. It is for people with acute myeloid leukemia that has returned or not responded to previous chemotherapy.

Wuhan, Hubei
NCT07617285Recruiting· Phase 1
CAR-T cell therapy for relapsed or refractory acute myeloid leukemia

This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.

Beijing
NCT05995041Not yet recruiting· Phase 1
Universal CAR-T cells for acute myeloid leukemia

This trial tests a type of immunotherapy called CAR-T cells that are made to target leukemia cells. The cells are designed to attack AML by recognizing several proteins on the cancer cells, and may be an option for patients who have not responded well to other treatments.

Shenzhen, Guangdong
NCT07201727Not yet recruiting· Early Phase 1
CAR-T cell therapy plus stem cell transplant for relapsed AML

This trial tests a combination of CAR-T cell therapies (targeting CD123, CLL-1, and CD7) followed by a stem cell transplant for people with acute myeloid leukemia that has returned or not improved. The goal is to see if this approach can help eliminate the leukemia and prepare for a transplant.

NCT07645469Recruiting· Phase 1
WT1-targeting T cells with azacitidine for AML

This trial tests a new type of cell therapy for people with acute myeloid leukemia (AML) that has minimal residual disease (small amounts of cancer left after treatment). The therapy uses your own immune cells, modified to target a protein called WT1 on leukemia cells, and combines it with a drug called azacitidine.

Seattle, Washington
NCT03326921Recruiting· Phase 1
T cell treatment for leukemia after a bone marrow transplant

This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.

Seattle, Washington

Hear when a new AML trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.